Lumacaftor/ivacaftor-associated health stabilisation in adults with severe cystic fibrosis.

This real-world evaluation study demonstrated benefits over several clinical domains (infective exacerbations requiring hospitalisation, IVABs, pulmonary function decline and nutritional parameters) in CF patients with severe lung disease.